Global /Australia /Healthcare /Biotechnology /PTX

Prescient Therapeutics Ltd.

PTX

• ASX: PTX • Delayed

0.0510AUD 0%

0.0359 USD

As of 14 June 2026, Prescient Therapeutics Ltd. has a market cap of $37.7M USD, ranking #32595 globally and #842 in Australia. It ranks #2941 in the Healthcare sector, and #566 in the Biotechnology industry.

Global Rank

32595

Country Rank

842

Sector Rank

2941

Industry Rank

566

Key Stats

Market Cap

$37.7MUSD

53.63M AUD

Enterprise Value

$31.09MUSD

44.13M AUD

Revenue (TTM)

$3.0MUSD

4.27M AUD

Net Income (TTM)

-$6.23MUSD

-8.86M AUD

Profit Margin

-208%

PS Ratio

12.6

PB Ratio

3.2

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Biotechnology

CEO

James McDonnell open_in_new

Employees

Founded

1986

Website

ptxtherapeutics.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-5.6%	-3.8%	-33%	2%	-39%	8.5%	-47%	-47%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	PTX Prescient Therapeutics Ltd ISIN: AU000000PTX3 Shares Out.: Shares Outstanding: 1.052B¹ Shares Float: 968.61M² TV: TradingView: ASX: PTX SA: Stock Analysis: ASX: PTX YF: Yahoo Finance: PTX.AX GF: Google Finance: ASX: PTX BA: Barron's: PTX MS: Morningstar: XASX: PTX	0.0510 AUD	TV: TradingView: ASX: PTX SA: Stock Analysis: ASX: PTX YF: Yahoo Finance: PTX.AX GF: Google Finance: ASX: PTX BA: Barron's: PTX MS: Morningstar: XASX: PTX

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Prescient Therapeutics Ltd.

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

Similar Companies

Industry: Biotechnology (Australia)

Name	Market Cap (USD) diff.	PE	Country
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 112K%	29.3	Australia
Telix Pharmaceuticals Ltd. ASX: TLX	$3.58B 5.09B AUD 9K%	-	Australia
Mesoblast Ltd. ASX: MSB	$2.02B 2.88B AUD 5K%	-	Australia
PolyNovo Ltd. ASX: PNV	$490.46M 697.75M AUD 1K%	71.8	Australia
Kazia Therapeutics Ltd. NASDAQ: KZIA	$141.64M 276%	-	Australia
Immutep Ltd. ASX: IMM	$65.26M 92.84M AUD 73%	-	Australia

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 484K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 424K%	19.0	United States
argenx SE EBR: ARGX	$47.84B 41.39B EUR 127K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 119K%	35.5	South Korea
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 112K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 74K%	43.8	South Korea

chevron_leftBack